An Open-Label Multi-Center Phase II Study of Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
Latest Information Update: 22 May 2025
At a glance
- Drugs Atezolizumab (Primary) ; Tocilizumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 15 May 2025 Planned End Date changed from 28 Feb 2025 to 30 Apr 2026.
- 15 May 2025 Planned primary completion date changed from 28 Feb 2025 to 30 Apr 2026.
- 15 May 2025 Status changed from active, no longer recruiting to recruiting.